INTRODUCTION
In both man and animals, oral phosphate administration has been repeatedly shown to cause a decrease in the urinary excretion of calcium (1) and a net increase in the total body retention of calcium. In vitro, in parathyroid hormone-induced resorption in tissue culture preparations, the movement of calcium from the bone is prevented by adding phosphate to the culture medium (2, 3). As a result, it has been suggested that phosphate supplements will cause a net increase in bone mass by either increasing bone formation or decreasing bone resorption. For this reason, phosphate supplementation has been used to treat healing fractures (4) and has been sugReceived for publication 20 March 1972 and in revised form 24 July 1972. gested as potentially useful in the therapy of metabolic bone disease (5, 6) . However, recent work has put in doubt the rationale behind its use in metabolic bone disease. Apart from the dangers of producing soft-tissue calcification (7) , measurements of serum parathyroid hormone (PTH)' (8) and bone turnover have suggested that oral phosphate supplements may in fact result in increased bone loss (9, 10) .
The present experiment was designed to measure directly the effects of a high daily intake of phosphate on PTH secretion and bone turnover and to discover the site of calcium retention in the body.
METHODS
Initial control studies. 10 adult female mongrel dogs were maintained for 6-18 months on a standard laboratory diet.2 At the end of this time the dogs weighed 13.1±1.7 kg (mean +SD). They were then placed on a control diet' for 6 wk. Three fasting, morning blood samples (1 wk between samples) were then obtained to establish normal calcium (11) , phosphate (12) , alkaline phosphatase (13) , magnesium (11) , and blood urea nitrogen values (14) . Serum immunoreactive PTH was also measured by using a single antiserum to bovine PTH, prepared in a rooster (15) . The final dilution volume was 1: 7500 in an incubation volume of 0.3 ml. The immunologic cross-reactivity between canine and bovine PTH was sufficient to permit detection of circulating PTH in normal dog sera. Sera from parathyroidectomized dogs contained no assayable PTH. All test sera gave assay curves parallel to the standard curve. The coefficient of variation of replicate samples at two widely different concentrations was 10%. In addition, control 24-hr urinary calcium (10) 
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The Journal of Clinical Investigation Volume 51 November 1972 mg/kg) to mark new mineralizing bone surfaces. The tetracycline was given intravenously, twice at a 10 day interval. 1 month later, 47Ca (10 ,Ci/kg) was given intravenously as a tracer for calcium, and disappearance of the isotope from blood was measured over a 5 day period (1 ml of heparinized whole blood was mixed with 1 ml of water and counted in a Picker automatic 4 7r counter, Picker Nuclear Co., White Plains, N. Y.). No difference was found between freshly mixed blood and samples in which settling had occurred. Total body retention of 47Ca was determined, in anesthetized dogs lying on their stomachs, by using a single crystal approximately 21 ft from the dog. Measurements were made before the isotope injection, immediately after, and 3 and 4 days later.
Measurements (17) of bone mineral content were made using the Cameron-Sorenson apparatus; previous studies 4 had shown that the method gives reproducible results in the area of the distal tibia. Initial control values were obtained from the left tibia at a point one-third of the total length of the bone, measuring from the distal end. The skin was shaved and tattooed to ensure a fixed point for subsequent measurements. Bone mineral content was measured three times during the control period, at weekly intervals. The measurement represented the scan area of the absorbed energy of a "2I source. The width of the tibia was determined by measuring the width of the scan area at the 0.75 base line level (18) . Bone biopsy specimens were taken from the midshaft of the right ulna and from the iliac crest, and cross-sections of mineralized bone were prepared for quantitative microradiography to assess bone turnover (19 (12) , and magnesium (11) and 24 hour urinary calcium (10) and phosphate were measured at intervals; serum immunoreactive parathyroid hormone (15) was measured at the end of the 6 months. Ulna and iliac crest bone biopsy specimens were taken again at the end of the study, from the corresponding site on the side opposite that sampled in the control period; sections were cut and prepared for quantitative microradiography. Soft-tissue samples from the heart, kidney, thoracic and abdominal aorta, gluteus muscle, and hamstring tendon were taken for estimation of calcium content. In addition, seven dogs which had been maintained on the standard laboratory diet were killed and similar soft-tissue samples were taken for estimation of the calcium content.
Experimental dogs. 10 adult female dogs were used. At the end of the control period, phosphate was added to the control diet (10 tablets of Hyper-Phos-K [The Kendall Co., Needham Heights, Mass.] to give a total daily intake of approximately 2.8 g of phosphorus/dog). This supplementation was maintained for 4 months and, then increased to 12 tablets/day for a further 6 months (a daily intake of 3.1 g). No complications developed except for sporadic diarrhea during the first few days of phosphate supplementation.
Measurements were made of serum calcium (11), magnesium (11), and phosphate (12) at monthly intervals for 10 months (20) . Urinary calcium (10) and phosphate were measured at 1 and 10 months. Serum was obtained at 5 and 10 months for PTH immunoassay (15) . Serum was obtained at 8 months for measurement of blood urea nitrogen (14) . 5 days before the dogs were killed, the 47Ca studies were repeated.
The dogs were given tetracycline orally (20 mg/kg) every other day, four times, and then were killed 40 hr after the last tetracycline dose. Alizarin red was injected to identify the last label of tetracycline. Immediately before the dogs were killed, an ophthalmologic examination was performed to evaluate the development of cataracts. At autopsy all the viscera were examined closely. Specimens from heart, kidney, thoracic and abdominal aorta, gluteus muscle, and hamstring tendon were saved for estimation of calcium content. The tissue samples were dried, acetone extracted to remove fat, ground, weighed, and dissolved in 3 ml of concentrated HCl. The solution was diluted with 3 ml of distilled water and the calcium concentration was measured with an atomic absorption spectrophotometer (10) . Samples of these same tissues were also taken and fixed in neutral formalin for histologic examination by von Kossa's stain.
Bone mineral content and bone diameter were measured at the end of 5 and 10 months of the experimental period; in two animals the bone diameter measurement exceeded the pretreatment value by 15%, indicating that the original (Table I). 4"Ca disappeared from the blood faster after treatment than before treatment (Table II) . The total body retention at 96 hr after injection was higher when compared with control values.
The bone turnover, as measured by quantitative mnicroradiography, was significantly changed. In the ulna, the amount of bone formation decreased by a factor of 2.5 while bone resorption doubled; in the iliac crest, bone resorption was markedly increased (Table III) . Bone formation rates (from tetracycline labeling) were unaltered by phosphate supplementation. Microscopically, the bone was more porous, with twice as many holes per cross-section at the end of the phosphate-supplement period (Fig. 1) (Table IV) . The loss of bone mass was significantly correlated with tue increase in boiie resorption and in I)orosity in the ut1ba (' Table ) .
Tlhe serum ininiunoreactivye PTH levels xvere within the normal range in all l)iut one dog during the coiitrol period; they increased as a result of phosphate suppleientation ( P < 0.005 ) in all but oiie dog (Fig. 2) . PTH changes correlated l)ositivelv w-ith the decrease in bone mineral content and wvith the chalige in bone resorption in the iliac crest and negatively with the serum ihosphate (Table V) . Bone resorption also correlated negatively with serum plhospllate levels.
After treatment, scattered calciuii deposits were found in the lenses of 8 of 10 dogs: in 5 of the 8 the calcium deposits were associated wvith changes compatible with cataracts. The calcium conteiit was increased significantly in the tendon, thoracic aorta, kidneys, and heart as compared wvith tissues of 10 normal dogs (Table VI) . Histo- cylinder generally found in the medulla (Fig. 3a) ; a less frequent finding was a nonuniform tubular deposit composed of medium-sized granules (Fig. 3b) no response by the skeleton, either as a decrease in resorption or a net increase in formation. In previous studies in dogs, renal insufficiency has resulted in an increase in circulating immunoreactive PTH when the oral phosphate levels were normal; the increase could be prevented by a low phosphate intake (15) . In the presence of normal kidney function, a relatively small increase in oral phosphate intake in the present animals resulted in loss of bone mass mediated by increased PTH secretion. It has been suggested (22) that the mechanism is through a transient hyperphosphatemia which induces hypocalcemia which in turn stimulates PTH secretion. The latter would tend to restore the serum calcium levels to normal and depress the serum phosphate. In the present study there was a slight but significant decrease in the fasting (morning) serum phosphate value, which reflected the development of secondary hyperparathyroidism. The negative correlation between these two expressions of increased parathyroid hormone secretion-serum phosphate decrease and bone resorption increase-suggests that, in individual dogs, the higher the PTH level, the greater the influence on both the serum phosphate and stimulation of bone resorption. The decrease in urinary calcium and the increase in isotope retention reflected total body retention of calcium and confirms previous studies in both animals and man which showed that phosphate supplements result in increased body retention of calcium (23, 24) . Previously it had been suggested that the skeleton is the site of calcium retention, which had led to the hope that calcium retention reflected a bone mass increase (2, 3). However, the present studies show that the calcium is deposited in all tissues and particularly in specific soft tissues such as the kidney. In vitamin D-induced hypercalcemia in rats, phosphate supplementation resulted in calcification of heart muscle and kidney, which proved fatal in some animals (7) . Calcification also may occur in the absence of hypercalcemia; previous studies in this labora- tory in adult normocalcenmic rabbits demonstrated calcification of both kidney and thoracic aorta as a result of oral phosphate supplementation (10) . In the adult dogs in the present study, chemical evidence of soft-tissue calcification and histologic evidence of calcification in the lens of the eye and in the kidney is seen in the absence of high serum calcium and phosphate levels in fastingstate samples. It is clear that, while many studies of the treatment of hypercalcemia in man have failed to show calcium deposits in tissues (20) , this judgment depends on the absence of gross deposits of mineral evident to the eye. The present investigation strongly suggests that accumulation of calcium occurs throughout the body in the majority of soft tissues and that it need not be preceded by hypercalcemia.
Although the sequestration of mineral in soft tissue is the most serious complication of phosphate supplementation, the effect on bone through parathyroid gland stimulation is possibly a more common medical problem. It is true that the average person ingests approximately 1-l-2 times as much phosphate as calcium in the diet. It has been shown, in short-term studies in man (8) and now in long-term studies in dogs, that phosphate ingestion results in increased PTH levels. Recently, in a group of untreated osteoporotic patients the phosphate intake was related to their bone resorption level (25) . In animals, bone loss or osteoporosis resulted from a dietary phosphorus-to-calcium ratio greater than 1; only, when the intake ratio was close to or less than 1 was bone mass unchanged (10) .
Apart from the reflection the present study has on the etiology of osteoporosis, it is probable that phosphate supplementation will aggravate, not reverse, bone-loss disorders, including metabolic bone diseases such as osteoporosis. The dose used in the study was higher than that customarily used in man; however, lower doses over a longer period may have similar effects. The increase in soft-tissue calcium would also contraindicate the use of phosphate in the treatment of hypercalcemia unless this was a life-threatening condition unresponsive to other fornms of treatment.
